ArticleUrologie (Heidelberg, Germany)2026
[Diagnosis and treatment of upper tract urothelial carcinoma: assessment of guideline compliance from 2011-2024].
Article in Urologie (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUpper tract urothelial carcinoma (UTUC) requires a complex, multimodal, and guideline-based therapeutic approach. However, due to the rarity of the disease, low case numbers, and diagnostic challenges, implementation of the annually updated European Association of Urology (EAU) guidelines in daily clinical practice is often difficult. The aim of this study was to evaluate guideline-compliant care and the influence of guideline-deviating treatment decisions on oncological outcomes. MATERIALS AND
methodsIn a retrospective analysis, 181 patients with UTUC who were treated at our clinic between 2011 and 2024 were examined. Diagnosis, therapy, and oncological outcome were evaluated based on the applicable EAU guidelines, and treatment courses were analyzed in relation to guideline adherence.
resultsIn all, 13% of patients received nonguideline-compliant diagnosis or therapy. The main causes were lack of bladder cuff resection (52%), lack of adjuvant chemotherapy (32%, 2020-2024), lack of interdisciplinary tumor board discussion (17%), and surgical undertreatment (5%). The lack of bladder cuff resection was associated with a significantly reduced overall survival (p = 0.047) and an increased recurrence rate (p = 0.038). In addition, there were repeated deviations in the comprehensive diagnostics for the correct classification of low-risk and high-risk patients.
conclusionDespite clear recommendations from the EAU, their implementation in everyday clinical practice remains challenging. However, guideline-based care is essential, as deviations are associated with significantly poorer oncological outcomes.
Indexed as
Identifiers
42484868What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.